Q-omics provides the consensus-scored ALDH3B2 profile across patient tissues and cancer cell-line models. ALDH3B2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ALDH3B2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ALDH3B2 RNA expression shows 12,726 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where ALDH3B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH3B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH3B2 survival associations across molecular data types. ALDH3B2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH3B2 RNA expression–survival associations across cancer types. High ALDH3B2 expression shows unfavorable associations in KIRC, LUAD, SKCM and LIHC, but favorable associations in PRAD and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for ALDH3B2 RNA expression.
This table summarizes ALDH3B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ALDH3B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH3B2 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LUSC, LUAD, THCA and COAD. The KIRC box plot shows higher ALDH3B2 RNA expression in normal versus tumor tissue (log2 FC = −1.603, t-test p < 0.001).
This table shows molecular features associated with ALDH3B2 in patient tissues and cancer cell lines. In patient samples, ALDH3B2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ALDH3B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BREAST.
